ARC Masterclass: The Art and Science of Managing Amyloidosis On Demand Part 3 – Management of ATTR Amyloidosis

The goal of this series is to address the unmet needs in the amyloidosis community as well as raise overall awareness of amyloidosis.   In this series, clinicians will learn skills to identify, correctly diagnose, and treat amyloidosis patients in their clinical practice as well as when and how to refer to specialty centers. The attendees will also learn about the value of multidisciplinary teams, and how to build an amyloidosis program to best support patients. 

This session will focus on  Management of ATTR Amyloidosis

  1. Introduction
  2. Cardiac TTR
  3. Neurological Manifestations in TTR
  4. Use of PYP Scintigraphy
  5. Genetic Testing and Counseling
  6. Discussion: TTR Stabilizers


Support:

This program is supported in part by educational grants from, Akcea Therapeutics, Alexion Pharmaceuticals , Alynylam Pharmaceuticals , Eidos Therapeutics, Inc., Pfizer Inc. and supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

This curriculum is designed for a broad audience of clinicians involved in the care and treatment of patients with amyloidosis. The collective target audience will include General Cardiologists, Nuclear Cardiologists, Neurologists, Hematologists, Heart Failure Specialists, Heart Failure Nurses, and Echocardiographers.

Learning Objectives

Following this activity, participants will be able to:

  1. Identify signs, symptoms, and features that should raise suspicion for a potential diagnosis of amyloidosis.
  2. Outline the methods available for testing for amyloidosis, including possible limitations of specific tests.
  3. Discuss data from recent clinical trials outlining possible treatment and potential patients who would benefit.
  4. Identify challenges and possible barriers to treatment, including disease severity, financial burden, and potential outcomes.
  5. Apply clinical algorithms to case studies.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
  • 2.00 Participation
Course opens: 
05/15/2021
Course expires: 
12/31/2021

John Berk

 

 John Berk, MD
 Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine, Boston University School of Medicine

 

 

Jose Nativi-Nicolau

 

 Jose Nativi-Nicolau, MD
 Associate Professor; Cardiovascular Director, Amyloidosis Program, University of Utah and Huntsman Cancer Institute

 

 

Michael Polydefkis

 

 Michael Polydefkis, MD
 Professor of Neurology; Director, Cutaneous Nerve Lab, Johns Hopkins University School of Medi

 

 

Faculty Disclosure

Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Vaishali Sanchorawala, MD
CME Course Director
Director, Amyloidosis Center, Boston University School of Medicine
Planner is a consultant and on the advisory board for Abbvie, Janssen, Regeneron. 

Lisa Mendelson, BSN, MSN, ANP-BC
CNE Course Advisor
Assistant Professor of Medicine, Boston University School of Medicine
Planner has no relevant financial relationships to disclose. 

John Berk, MD
Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine, Boston University School of Medicine
Speaker is an ad-hoc consultant for Ionis, Akcea and Eidos. Speaker does plan on discussing unlabeled/investigational uses of a commercial product.

Jose Nativi-Nicolau, MD
Associate Professor; Cardiovascular Director, Amyloidosis Program, University of Utah and Huntsman Cancer Institute
Speaker receives research, consulting, education from Pfizer; research and consulting for Akcea/Ionis; research from Eidos; consulting for Alnylam. Speaker does plan on discussing unlabeled/investigational uses of a commercial product.

Michael Polydefkis, MD
Professor of Neurology; Director, Cutaneous Nerve Lab, Johns Hopkins University School of Medicine
Speaker receives grants and is a consultant for Alnylam, Ionis and Pfizer. Speaker is a consultant for Vertex and Biogen. Speaker does not plan on discussing unlabeled/investigational uses of a commercial product.

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Amyloidosis Research Consortium.  Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly-provided by Amyloidosis Research Consortium.

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Boston University School of Medicine designates this Enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 ANCC
    Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
  • 2.00 Participation
Please login or register to take this course.

In order to earn credit, please take the pre-test and watch the video. Once completing the post-test, with a 70% score or better, and the evaluation, you may claim your credit. Your certificate will be available immediately for download.
 

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTHCARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

©BUSM 2021. All Rights Reserved.